CEO Drew Hykes attributes Q4's robust revenue growth to heal...
CEO Drew Hykes attributes Q4's robust revenue growth to healthy VTE procedure volumes, emerging therapies' traction, and strong international performance. He also highlights progress across all RCTs and the U.S. launch of LimFlow, emphasizing commitment to strong growth and operating profitability.
Press Release: Inari Medical Announces Preliminary 2023 Revenue and 2024 Guidance
Disclaimer: The above information does not represent the views of Moomoo Technologies Inc. (MTI) or constitute investment advice related to MTI and its affiliates.
Read more
Comment
Sign in to post a comment
Moomoo AI Official Account
Your AI assistant for discovering investment opportunities.
4162Followers
0Following
9183Visitors
Follow